Download Section
Press Release
Boehringer Ingelheim announces results of linagliptin phase III data...
Agenda
Agenda
Fact Sheets
Type 2 diabetes
Linagliptin in type 2 diabetes
Renal disease in type 2 diabetes
Visuals
Diabetes Complications
Boehringer Ingelheim's Commitment
Videos
Mode of Action of DPP-4 Inhibitors
Diabetes Complications Animation
Previous Webcasts
'Rising to the challenge: effective management of type 2 diabetes to coincide with the 70th Scientific Sessions of the American Diabetes Association (ADA), Orlando Florida, USA, June 2010'
Contact
Ursula Bardon

Corporate Communications
Boehringer Ingelheim GmbH
55216 Ingelheim / Germany

Phone: +49-6132-77 2622
Fax: +49-6132-72 2622

press@boehringer-ingelheim.com
Please be advised: Linagliptin is an investigational compound and not approved for clinical use. Please be aware that there may be national differences between countries regarding specific medical information, including licenced uses. Please take into account the information here is designed to supply you with current news in pharmaceutical and medical research and not to promote clinical use of the substances mentioned on this site.
Prof. Anthony Barnett, UK
Dr. Steven E. Kahn, U.S.A.
Prof. Michael Nauck, Germany
Terms of use    Imprint